ZURICH (Reuters) -Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries.
The drug failed to show an improvement in sustained remission among patients with newly diagnosed or relapsing GCA, a condition that affects people aged mainly over 50 and can cause vision loss and life threatening aneurysms, Novartis said.
“While the Phase III results… did not replicate the positive outcomes observed in the Phase II trial, we remain committed to continuing to drive scientific progress and deepening the understanding of immune-mediated diseases,” said Shreeram Aradhye, president of development and chief medical officer at the company.
(Reporting by John Revill, Editing by Miranda Murray)
Comments